Analysts predict that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will announce earnings per share of ($0.67) for the current quarter, Zacks reports. Zero analysts have made estimates for Zynerba Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.73). Zynerba Pharmaceuticals reported earnings per share of ($0.60) during the same quarter last year, which would suggest a negative year-over-year growth rate of 11.7%. The business is expected to report its next earnings report on Monday, March 11th.
According to Zacks, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($2.87) per share for the current year, with EPS estimates ranging from ($2.94) to ($2.79). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.43) per share, with EPS estimates ranging from ($2.77) to ($1.84). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Zynerba Pharmaceuticals.
Several research firms have recently issued reports on ZYNE. Zacks Investment Research cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, January 27th. Cantor Fitzgerald set a $21.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 17th. HC Wainwright set a $23.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 13th. Finally, ValuEngine cut Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Zynerba Pharmaceuticals has an average rating of “Hold” and an average price target of $15.88.
Shares of ZYNE stock traded down $0.11 during mid-day trading on Friday, hitting $5.22. 531,395 shares of the company’s stock were exchanged, compared to its average volume of 1,026,503. Zynerba Pharmaceuticals has a fifty-two week low of $2.75 and a fifty-two week high of $12.50. The stock has a market capitalization of $91.15 million, a price-to-earnings ratio of -2.10 and a beta of 4.98.
A number of institutional investors have recently modified their holdings of the stock. Raymond James & Associates acquired a new position in shares of Zynerba Pharmaceuticals during the second quarter worth about $164,000. Millennium Management LLC lifted its stake in shares of Zynerba Pharmaceuticals by 116.0% during the second quarter. Millennium Management LLC now owns 224,511 shares of the company’s stock worth $2,187,000 after purchasing an additional 120,570 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Zynerba Pharmaceuticals during the second quarter worth about $239,000. Engineers Gate Manager LP lifted its stake in shares of Zynerba Pharmaceuticals by 179.8% during the third quarter. Engineers Gate Manager LP now owns 66,270 shares of the company’s stock worth $541,000 after purchasing an additional 42,583 shares in the last quarter. Finally, Zeke Capital Advisors LLC acquired a new position in shares of Zynerba Pharmaceuticals during the third quarter worth about $193,000. Hedge funds and other institutional investors own 15.32% of the company’s stock.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Featured Article: How To Calculate Debt-to-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.